For all inquiries regarding Tissue Microarrays with survival data, please contact us at support@taibsbio.cn
首页 > 组织芯片 > > DLV483
tissue microarray-DLV483
  • 点数:
    48
    例数:
    48
    点样直径(mm):
    2
    厚度(µm):
    5
    行数:
    6
    列数:
    8
    组织阵列类型:
    FFPE
    种属:
    Human
DLV483
加入收藏

描述: Liver cancer with liver tissue array, including pathology grade, TNM and clinical stage, 48 cases/48 cores

详情: Liver carcinoma with liver tissue microarray, containing 35 cases of hepatocellular carcinoma, 5 cholangiocellular carcinoma and 8 adjacent normal liver tissue, single core per case

应用程序: Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page

备注

1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers."

  • 说明书列表
  • 重复病例
  • 下载说明书
图表:
Liver
  • Malignant(II)
  • Malignant(IIIA)
  • Malignant(IVA)
  • NAT(*)
  • _ma
组织芯片
DLV483
1
2
3
4
5
6
7
8
A
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
B
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
C
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
D
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
E
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
F
Liv
Liv
Liv
Liv
Liv
Liv
Liv
Liv
_ma
DLV483
  • 年龄:
  • 性别:
  • 器官/解剖部位:
  • 病理诊断:
  • 等级:
  • 分期:
  • 阶段:
  • 组织ID.:
  • 类型:
位置 No. Age Sex Organ/Anatomic Site Pathology diagnosis Grade TNM Stage Type Tumor size Ki-67 CK18
A1
1 52 M Liver Hepatocellular carcinoma with sparse necrosis 1 T3N0M0 IIIA Malignant 14*9*5.5 +,2% +,60%
A2
2 38 M Liver Hepatocellular carcinoma 1 T3N0M0 IIIA Malignant 9*8*5.5 +,5% +++,100%
A3
3 45 M Liver Hepatocellular carcinoma 1 T2N0M0 II Malignant 5.0*4.0*4.0 +,5% +++,100%
A4
4 56 M Liver Hepatocellular carcinoma 1--2 T3N0M0 IIIA Malignant 9*7*5.5 - ++,90%
A5
5 40 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 15*11*16 - ++,90%
A6
6 58 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant - - ++,70%
A7
7 63 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant - +,2% +,40%
A8
8 48 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 8*6*4.5 - +,60%
B1
9 62 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 10*5*4 +,5% ++,70%
B2
10 74 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 10*9*8.5 - +,30%
B3
11 50 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 9*4*2.5 - ++,60%
B4
12 24 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 5*4*2.5 - +++,100%
B5
13 50 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 11*5*3.5 +,5% ++,90%
B6
14 55 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 10*5*4.8 +,5% +,70%
B7
15 62 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 4*3*3 - +,60%
B8
16 57 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 7.5*4*3 - +,40%
C1
17 51 F Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 8*4*2 - +,70%
C2
18 54 F Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 12*7.5*3.5 +,3% +,90%
C3
19 45 M Liver Hepatocellular carcinoma 2 T3N0M0 IIIA Malignant 12*8*4.5 ++,35% +,70%
C4
20 40 M Liver Hepatocellular carcinoma with sparse necrosis 2 T3N1M0 IVA Malignant 5 +,5% ++,80%
C5
21 58 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 5.5*4.0*2.0 +,5% ++,50%
C6
22 53 F Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 6.0*5.0*4.0 +,15% ++,80%
C7
23 52 F Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 6.0*4.5*4.5 +,10% +,60%
C8
24 36 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 12*8*7.5 +,3% +,60%
D1
25 36 M Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 12*8*7.5 - ++,80%
D2
26 72 F Liver Hepatocellular carcinoma 2 T2N0M0 II Malignant 5.5*5.0*3.5 - ++,80%
D3
27 63 M Liver Hepatocellular carcinoma 2--3 T3N0M0 IIIA Malignant - +,3% ++,50%
D4
28 62 M Liver Hepatocellular carcinoma 2--3 T3N0M0 IIIA Malignant 6.0*4.0*3.0 - ++,70%
D5
29 65 F Liver Hepatocellular carcinoma (degeneration) 2--3 T2N0M0 II Malignant 15*8.5*3.5 - ++,80%
D6
30 51 M Liver Hepatocellular carcinoma with necrosis 3 T3N0M0 IIIA Malignant 9*6*5.5 - +,40%
D7
31 62 M Liver Hepatocellular carcinoma 3 T2N0M0 II Malignant - +,10% ++,80%
D8
32 49 M Liver Hepatocellular carcinoma 3 T2N0M0 II Malignant 10*7*4 - ++,80%
E1
33 60 F Liver Hepatocellular carcinoma with necrosis 3 T3N0M0 IIIA Malignant 7*6*5 +,15% +,20%
E2
34 47 M Liver Hepatocellular carcinoma 3 T3N0M0 IIIA Malignant 8.5*6.0*3.5 - ++,60%
E3
35 60 M Liver Hepatocellular carcinoma 3 T3N0M0 IIIA Malignant 8.0*7*5 - +,40%
E4
36 46 F Liver Cholangiocellular carcinoma 2 T2N1M0 IVA Malignant - +,3% ++,70%
E5
37 54 M Liver Cholangiocellular carcinoma 2 T3N1M0 IVA Malignant 9 +,5% ++,90%
E6
38 51 F Liver Cholangiocellular carcinoma 2 T3N1M0 IVA Malignant 7 - +,30%
E7
39 51 M Liver Cholangiocellular carcinoma (degeneration) 3 T3N1M0 IVA Malignant - - ++,70%
E8
40 70 F Liver Cholangiocellular carcinoma 3 T3N1M0 IVA Malignant 10*10 - +,40%
F1
41 41 F Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - +,20%
F2
42 65 F Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - +,20%
F3
43 47 M Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - ++,80%
F4
44 46 M Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - +,3% ++,70%
F5
45 52 F Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - +,80%
F6
46 59 M Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - +,40%
F7
47 54 M Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - - +,30%
F8
48 58 M Liver Adjacent normal liver tissue (mild inflammation) * * * NAT - +,3% +,30%
_marker_
查找与该芯片存在重复病例的芯片:
如需了解产品规格方面的任何问题,请联系我们:support@arraysbank.com
0.074084s